FDA clears Xtrak's thrombectomy catheter:
This article was originally published in Clinica
The US FDA has given Xtrak Medical clearance to market its first product - a catheter system for removing blood clots from haemodialysis vascular access grafts. The XTD thrombectomy system is a low-profile, wall-contacting catheter that simultaneously pulverises and removes thrombus from the occluded grafts. A clinical study with the system demonstrated "excellent" technical success and three-month patency rates with very low complications, says the Salem, New Hampshire company. The XTD system is also already CE-marked for sale in Europe.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.